Atlas Trials

Safety and Efficacy of Bevacizumab Plus RAD001 Versus Interferon Alfa-2a and Bevacizumab for the First-line Treatment in Adult Patients With Kidney Cancer

Clinical trial NCT00719264 · COMPLETED

Trial details

NCT number
NCT00719264
Sponsor
Novartis Pharmaceuticals
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
CarcinomaAdenocarcinomaRenal CellNephroid CarcinomaHypernephroid
Start date
2008-11-12
Primary completion
2011-12-31
Enrollment
365

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.